Gilead outbids Astellas for CV Therapeutics

Gilead Sciences is to buy CV Therapeutics for $1.4 billion, or $20 per share. The move deals a blow to Astellas's efforts to buy CV, which the Japanese company had been courting for $1 billion, or $16 per share, since November.